Document Detail

Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy.
MedLine Citation:
PMID:  22314429     Owner:  NLM     Status:  Publisher    
BACKGROUND & AIMS: In a previous study, advanced fibrosis was associated with worsening efficacy of antiviral therapy in HCV-transplant patients. We aimed to assess whether changes in treatment policy, that is starting therapy at lesser stages of fibrosis, have resulted in improved efficacy. METHODS: Efficacy (rapid, early, end-of-treatment and sustained viral response- SVR) and tolerability (peginterferon-pIFN/ribavirin-RBV doses, premature discontinuation, dose reductions, anemia, growth factors, transfusions) were compared between 2 non-contemporaneous cohorts of post-LT naïve patients treated with pIFN-RBV: Group 1 (n=44), a historical cohort of patients treated in 2005-07 and Group 2 (n=70), patients treated more recently (2007-10), where treatment was started once there was evidence of fibrosis: RESULTS: SVR increased from 25% to 54% (p=0.002) due to a reduction in relapse rate. Comparing both cohorts, a decrease in the number of cirrhotic patients together with an increase in platelet count was observed in recent years. Additional non-intentional changes included: (i) an increase of patients treated under cyclosporine immunosuppression, (ii) treatment-related factors with an increase in patients treated with initial full pIFN and RBV doses, who developed anemia and hence required dose modifications and erythropoietin. Baseline factors associated with SVR were younger donor age, lack of cirrhosis or severe necroinflammation and the use of RBV at full doses at initiation while on-treatment variables were adherence and viral kinetics. CONCLUSIONS: Treatment in the absence of cirrhosis is associated with higher SVR warranting strict disease progression monitoring. A more aggressive approach, particularly regarding RBV dosage, is also associated with improved efficacy. Further studies are required to assess whether switching to cyclosporine will result in improved SVR.
Marina Berenguer; Victoria Aguilera; Angel Rubín; Cecilia Ortíz; Martina Jimenez; Martín Prieto
Related Documents :
22281789 - Changes in bnp, hs-crp and timi risk index with addition of tirofiban during primary pe...
22301429 - Lower limb lengthening and deformity correction using the fitbone motorized nail system...
22398159 - A double blind randomized cross over trial comparing rate of decortication and efficacy...
15353899 - Retrolective, comparative, epidemiological cohort study with parallel groups design for...
18077809 - Corticosteroids for bacterial meningitis in adults in sub-saharan africa.
22869389 - A comparison of bleeding complications post-ablation between warfarin and dabigatran.
17679669 - Visual function at baseline and 1 month in acute optic neuritis: predictors of visual o...
11854729 - Lysis/balloon angioplasty versus thrombectomy/ open patch angioplasty of failed femorop...
1389199 - Low back pain following epidural blood patch.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-4
Journal Detail:
Title:  Journal of hepatology     Volume:  -     ISSN:  0168-8278     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier B.V.
Liver Transplantation and Hepatology Unit, La Fe Hospital, Valencia, Spain; Ciberehd (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas); University of Valencia, Faculty of Medicine, Valencia, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE)...
Next Document:  IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty...